Sort   by:  
 Page size 
MetabolomicsVesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer

Selective autophagy of mitochondria is known to promote survival and progression of cancer cells in various malignancies, including triple-negative breast cancer (TNBC). Here, we investigate the essential metabolic adaptations that support mitochondrial quality control in cancer cells with the ai...

2025-09-30 | MTBLS13037 | MetaboLights
MetabolomicsThe Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells
Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribo...
2016-11-07 | MTBLS337 | MetaboLights
MetabolomicsCommon Metabolic Pathways Implicated in Resistance to Chemotherapy Point to a Key Mitochondrial Role in Breast Cancer
Cancer cells are known to reprogram their metabolism to adapt to adverse conditions dictated by tumor growth and microenvironment. A subtype of cancer cells with stem-like properties, known as cancer stem cells (CSC), is thought to be responsible for tumor recurrence. In this study, we demonstrated ...
2019-08-19 | MTBLS678 | MetaboLights
MetabolomicsIntegrative Analysis of Trichosanthes kirilowii Maxim Formula Granules’ AntiTriple-Negative Breast Cancer Mechanism via Network Pharmacology, Metabolomics, and Molecular Pharmacology

Background: Triple-negative breast cancer (TNBC) urgently needs effective therapies due to limited targeted options and unfavorable outcomes. We investigated Trichosanthes kirilowii Maxim formula granules (TKM) using integrated network pharmacology, metabolomics, and molecular pharmacology to cla...

2026-02-15 | MTBLS13902 | MetaboLights
MetabolomicsMulti-omic Analysis of ClpP Activation in Triple-Negative Breast Cancer Cells
Not available
ORGANISM(S): Homo sapiens 
ST002408 | MetabolomicsWorkbench
OtherThe proteomic landscape of triple-negative breast cancer
Data from ProteomicsDB, ID: PRDB004167. Experiment: MCF10A_Trypsin_rep1, file: folder summary. Published as part of Cell Rep. 2015 Apr 15. pii: S2211-1247(15)00341-1 . From the Abstract: {{i}} Triple-negative breast cancer is a heterogeneous disease characterized by poor clinical outcomes and a sho...
ORGANISM(S): Homo_sapiens_viruses, Human_female 
GPM32320015247 | GPMDB
TranscriptomicsTranscriptomes of triple negative breast cancer enriched breast cancer cohort
Breast cancers enriched for the triple negative breast cancer phenotype with extensive clinico-pathological features were profiled to establish their comprehensive transcriptional profiles
ORGANISM(S): Homo sapiens 
2016-11-21 | E-MTAB-5270 | biostudies-arrayexpress
TranscriptomicsCharacterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer
We performed whole transcriptome sequencing of human monocytes that were co-cultured with estrogen receptor positive (ER+) or triple-negative (TNBC) breast cancer cell lines and studied the biological responses related to the differential gene activation in both cell types to understand how differen...
ORGANISM(S): Homo sapiens 
2015-11-19 | E-GEOD-75130 | biostudies-arrayexpress
GenomicsLigand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer
Glucocorticoids (GC) have been widely used as coadjuvants in the treatment of solid tumors, but GC treatment may be associated with poor pharmacotherapeutic response and/or prognosis. The genomic action of GC in these tumors is largely unknown. Here we find that dexamethasone (Dex, a synthetic GC) r...
ORGANISM(S): Homo sapiens 
2015-09-18 | E-GEOD-56022 | biostudies-arrayexpress
TranscriptomicsTumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients
Evidence suggests that BRCA1 mutation associated tumors have increased sensitivity to DNA damaging agents like cisplatin. Sporadic triple negative breast cancers (TNBC) have many phenotypic similarities to BRCA1 tumors and may have a similar sensitivity to cisplatin. We tested the efficacy of cisp...
ORGANISM(S): Homo sapiens 
2009-11-04 | E-GEOD-18864 | biostudies-arrayexpress
Sort   by:  
 Page size